These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26935787)

  • 1. Characteristics of Pediatric Exposures to Antidementia Drugs Reported to a Poison Control System.
    Thornton SL; Pchelnikova JL; Cantrell FL
    J Pediatr; 2016 May; 172():147-50. PubMed ID: 26935787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease.
    Lampela P; Tolppanen AM; Tanskanen A; Tiihonen J; Lavikainen P; Hartikainen S; Taipale H
    Ann Med; 2017 May; 49(3):230-239. PubMed ID: 27786552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
    Inglis F
    Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidementia drug treatment in people screened positive for dementia in primary care.
    Wucherer D; Eichler T; Kilimann I; Hertel J; Michalowsky B; Thyrian JR; Teipel S; Hoffmann W
    J Alzheimers Dis; 2015; 44(3):1015-21. PubMed ID: 25391382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of Experience of a Statewide Poison Control Center With Pediatric Exposures to Oral Antineoplastic Drugs in the Nonmedical Setting.
    Thornton SL; Liu J; Soleymani K; Romasco RL; Farid H; Clark RF; Cantrell FL
    Am J Ther; 2016; 23(2):e377-81. PubMed ID: 23884076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of centrally acting cholinesterase inhibitor exposures in adults.
    McCain KR; Sawyer TS; Spiller HA
    Ann Pharmacother; 2007 Oct; 41(10):1632-7. PubMed ID: 17848422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse Drug Event Profile Associated with Anti-dementia Drugs: Analysis of a Spontaneous Reporting Database.
    Kose E; Yamamoto T; Tate N; Ando A; Enomoto H; Yasuno N
    Pharmazie; 2023 May; 78(5):42-46. PubMed ID: 37189266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of pneumonia in new users of cholinesterase inhibitors for dementia.
    Lai EC; Wong MB; Iwata I; Zhang Y; Hsieh CY; Kao Yang YH; Setoguchi S
    J Am Geriatr Soc; 2015 May; 63(5):869-76. PubMed ID: 25912671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Castor bean seed ingestions: a state-wide poison control system's experience.
    Thornton SL; Darracq M; Lo J; Cantrell FL
    Clin Toxicol (Phila); 2014 Apr; 52(4):265-8. PubMed ID: 24579983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use.
    Wübbeler M; Wucherer D; Hertel J; Michalowsky B; Heinrich S; Meyer S; Schaefer-Walkmann S; Hoffmann W; Thyrian JR
    BMC Health Serv Res; 2015 May; 15():205. PubMed ID: 25998147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristic effects of anti-dementia drugs on rat sleep patterns.
    Ishida T; Kamei C
    J Pharmacol Sci; 2009 Mar; 109(3):449-55. PubMed ID: 19305123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
    J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unintentional pediatric exposures to central alpha-2 agonists reported to the National Poison Data System.
    Wang GS; Le Lait MC; Heard K
    J Pediatr; 2014 Jan; 164(1):149-52. PubMed ID: 24094880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina].
    Rojas G; Demey I; Arizaga RL
    Medicina (B Aires); 2013; 73(3):213-23. PubMed ID: 23732196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs for cognitive loss and dementia.
    Treat Guidel Med Lett; 2013 Oct; 11(134):95-100; quiz 1 p following p100.. PubMed ID: 24081314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human bromethalin exposures reported to a U.S. Statewide Poison Control System.
    Huntington S; Fenik Y; Vohra R; Geller RJ
    Clin Toxicol (Phila); 2016 Mar; 54(3):277-81. PubMed ID: 26860212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system.
    Hernandez RK; Farwell W; Cantor MD; Lawler EV
    J Am Geriatr Soc; 2009 Nov; 57(11):1997-2003. PubMed ID: 19793162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deterioration in donepezil-induced PR prolongation after a coadministration of memantine in a patient with Alzheimer's disease.
    Igeta H; Suzuki Y; Motegi T; Sasaki A; Yokoyama Y; Someya T
    Gen Hosp Psychiatry; 2013; 35(6):680.e9-10. PubMed ID: 23731891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.